Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2 | P10415 | 9/20 | 0.44 |
| ▸ | NR1D1 | P20393 | 2/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.42 |
| ▸ | BAD | Q92934 | 3/20 | 0.42 |
| ▸ | PREP | P48147 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.41 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14259830 | 0.89 | NR1D1 (0.43) | NR1D1ACEPREPPOLBHTT | |
| SCHEMBL15675696 | 0.84 | OPRM1 (0.54) | BCL2ACEBADPREPOPRM1 | |
| SCHEMBL20738536 | 0.84 | OPRM1 (0.54) | BCL2ACEBADPREPOPRM1 | |
| SCHEMBL14067129 | 0.84 | OPRM1 (0.54) | BCL2ACEBADPREPOPRM1 | |
| SCHEMBL17559498 | 0.83 | BCL2 (0.47) | BCL2NR1D1ACEBADPOLB | |
| SCHEMBL4595358 | 0.83 | BCL2 (0.47) | BCL2NR1D1ACEBADPOLB | |
| SCHEMBL17559495 | 0.83 | BCL2 (0.47) | BCL2NR1D1ACEBADPOLB | |
| SCHEMBL24925818 | 0.81 | OPRM1 (0.49) | NR1D1ACEPREPPOLBHTT | |
| SCHEMBL24925917 | 0.81 | OPRM1 (0.49) | NR1D1ACEPREPPOLBHTT | |
| SCHEMBL24925839 | 0.81 | OPRM1 (0.49) | NR1D1ACEPREPPOLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019032-A1 | BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS | MAPK1, ALK, MAP3K1 | BCL2 969/4885NR1D1 637/4885ACE 4290/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.